The main objective of this paper is to analyse trade flows and tariff policies of health products.
INTRODUCTION
Health expenditures around the world have been growing strongly both in developed and in developing countries over the past decades. One key ingredient of every health system are physical goods that are directly used for diagnosis and treatment of patients or that are vital for other elements of the health system, such as laboratory equipment to conduct medical research. The other main ingredients are the delivery of health services and services related to public health (such as health insurance services, financial services, etc.). In an increasingly interconnected world, an ever larger share of these products and services is traded internationally. The objective of this paper is to analyse the development in international trade of health products and of the corresponding trade policies over the past fifteen years (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) . Due to the paucity of international services' trade data, we only look at international trade in health products and not in health services.
Despite the growing importance of public and private expenditures related to health, there is not yet an agreed international definition of the "universe" of health products. This paper constitutes the first attempt to construct such a "universe" using the product classification of the Harmonized System (HS) as a basis. The HS is a classification that was developed to clearly identify products that enter a country at the border and to be able to accord the respective treatment. Having been developed from a trade perspective, it does not offer the refinement which, from a public health perspective, would be desirable. However, we believe that it offers enough detail to assemble a list of health products which covers a substantial share of all health products that enter the public health sphere and thus offers interesting opportunities for analysis.
In trying to build up a comprehensive universe of health products, our study contrasts with previous studies which have focused only on a subset of health products. For example, Krasovec & Connor (1998) looked at tax exemptions for three product groups, namely vaccines, oral rehydration salts, and contraceptives. Olcay & Laing (2005) analyse tariffs on pharmaceutical products. Using this newly defined universe of health products, the paper analyses in detail international trade flows and trade policies applied to these products. It thus provides an important update and extension of previous studies, such as Olcay & Laing (2005) . Foreshadowing the results, we find that international trade in health products, and especially trade in dosified medicines, has developed in a very dynamic manner over the past fifteen years. The market of health products, measured by exportations and importations, is heavily dominated by developed countries, while developing countries are gaining ground only slowly. Finally, we observe that the tariffs have come down substantially in all country groups: Developed, developing, transition countries as well as LDCs.
However, even at a relatively low level, imposing tariffs still raises domestic prices for health products, especially for products with long supply chains.
The study is structured as follows: We first present the methodology used to establish the group of health products, followed by a short description of the data sources. In the section III the main results are presented and discussed. Finally, we summarize the main conclusions and suggest areas for future research.
II.
METHODOLOGY AND DATA
A. METHODOLOGY (a)
The Harmonized System Classification of international trade flows
Countries typically keep detailed records of goods that enter their domestic markets. In order to make national trade data comparable and in order to facilitate the exchange of goods across borders, the World Customs Organization has developed a classification for international trade in goods, the socalled Harmonized System (HS) which is now being widely used across the world. The HS classification dissects all trade flows into clearly distinguishable groups and breaks them down into 97 chapters and almost 6000 subheadings. It thereby follows a certain economic logic, mainly from crude products to more complex products and by sector of economic activity.
In this study, we are interested in all internationally traded goods that can contribute in one way or another to public health. Analysing in detail the HS classification (2007), we are able to identify 207 subheadings containing products which can be directly linked to a health purpose. In order to allow for further analysis, we regroup all 207 products into three groups (A, B, C) and five subgroups (A1, Figure 1 presents the all groups and subgroups in a schematic way. Group A covers all products and specific inputs into the pharmaceutical industry. Subgroups A1, A2 and A3 thus contain products that are either finished medicines (A1 and A2) or specific inputs into the pharmaceutical industry (A3).
Goods in groups B and C are produced by other industries. In the following we will explain in detail the composition of each of the six groups. • 300310 Medicaments Containing penicillins or derivatives thereof, with a penicillanic acid structure, or streptomycins or their derivatives
• 300320 Medicaments Containing Other Antibiotics
• 300331 Medicaments Containing Insulin
• 300339 Medicaments Containing Other Hormones
• 300340 Medicaments Containing Alkaloids or Derivatives Thereof
• 300390 Other Medicaments
From a public health perspective these HS subheadings might appear insufficient as they offer little details, making it difficult to detect the specific amount of certain medicines that are traded. For example, one might be interested to know which specific medicines, including the name and dosage, containing insulin were imported. The HS classification at the six digit level leaves these questions open. Several countries apply more specific goods classifications beyond the six-digit codes.
However, as these codes are not yet harmonized at the international level, it is not possible to use them for comparative statistical analysis.
The production of drugs requires certain inputs. The HS classification specifies 57 subheadings which are used explicitly for the production of pharmaceuticals. These inputs, which we label A3 (Inputs specific to the pharmaceutical industry), can be found in the following HS headings: 2935, 2936, 2937, 2939, and 2941. A detailed list of the 57 subheadings can be found in the Appendix 1 of this paper.
(ii) Group B
Obviously, not all inputs used in the production of pharmaceuticals are specific to that sector, but are also used in other industries. For example, under HS 292142 we find 'Aniline Derivatives', which are needed for the production of Paracetamol. At the same time, aniline derivates are used since the 19 th century as important ingredients for dyestuffs. Most of these chemicals that are used in the pharmaceutical industry and beyond fall under the HS Chapter 29 "Organic Chemicals".
There is yet no agreed international definition which formally establishes a list of organic chemicals that could be considered relevant inputs into the production of pharmaceuticals. At the international level the "Pharmaceutical Tariff Elimination Agreement" (PTEA) gives some indication which products might be regarded to be pertinent in this context. Second, we have identified medical technology equipment (C2), which encompasses all those products which are used either for diagnosis, such as ultraviolet or infra-red ray apparatuses (HS 901820), or in treatment, such as ozone therapy apparatuses (HS 901920) or artificial joints for orthopaedic purposes (HS 902111). Overall, group C contains 61 HS subheadings (28 in C1 and in 33 C2).
(iv) Caveats
One of the key challenges when working with the HS classification is that at the six-digit level one might capture products that are not used exclusively in the health sector, but also in other sectors Not only the trade flows recorder under HS 630493 are composed of different products, but also the custom duties for HS 630493 are an average of all tariff lines that a countries apply at a higher level of disaggregation to the different products within this specific HS code. As a consequence, the average custom duties for HS 630493 might appear substantive, even though malaria bed nets might enter the country duty free. The study of Simon, Larson, Zusman, & Rosen (2002) on the importance of lowering tariffs on insecticide treated bed nets suffer from this methodological challenge. The authors themselves state that "the ambiguous nature of the coding systems makes it difficult to determine accurate tariff rates for ITNs…" (Simon et al., 2002, p. 5) . In order to avoid this kind of problems, we have attempted to include only those subheading for which we had evidence that the use is predominantly for public health purposes or that included goods of multiple use, health being one of them (such as laboratory equipment). Following this logic, we decided to exclude the tariff headings such as HS 630493 from our sample.
Overall, the drawbacks of working with the HS subheadings are mainly twofold. First, as the example of the bed nets illustrates, a particular HS subheading might cover in its majority non-health related products. In order to guarantee a certain level of accuracy in the trade flows that we measure and that are related to public health, we find ourselves obliged to ignore international trade in some goods that actually do enter the public health space.
Second, in case products have multiple uses, and only one being for public health, we include in our trade statistics products which do not enter in their entirety the public health domain. The commodity group B (Chemical inputs of general purpose) is a good example for this problem, as chemical inputs of general purpose are needed in very many sectors.
In summary, using the HS classification at the six-digit (subheading) level we are on the one hand unable to capture all trade flows that contribute to public health, and on the other hand, we overstate some trade flows, since we are unable to fully discriminate between trade flows related to public health and those that are unrelated. The trade and tariff statistics that are presented in the sections below should therefore be interpreted with caution. -price-index-and-annual-percent-changesfrom-1913-to-2008/ 5 At the time of writing this study (July 2011) , not all countries had reported their trade flows for 2010. 6 The annual growth rate of world merchandise trade in value terms was about 6.1 per cent according to the WTO Statistics Database. A, B and C (1995-2009, Million USD) Development of international trade in health products by commodity groups A, B and C from 1995-2009 (in Million USD) Sources: COMTRADE, WTO Secretariat
Graph 1: Development of world trade of the three commodity groups
Comparing the evolution of trade in the three main commodity groups (A, B and C), we notice that the commodity group A constituted the largest share (in value terms) over the entire period, and at the same time, this group exhibited the strongest growth performance. It rose from around 37 billion USD International trade data on health products thus seems to be an excellent indicator of difference in health spendings across different country groups.
Graph 3: Imports of health products by country group (1995-2009)

Source: COMTRADE, WTO Secretariat
Let us now turn to the share between the four country groups for exports of health products (Graph 4).
The export market is even more strongly dominated by developed countries than global imports. Until In order to explain the dominance of developed countries in the export of health products, one would need to analyse several economic variables which is beyond the scope of this paper. We therefore would limit ourselves to some rather general explanation. First of all, the production of the majority of the health products included in our sample requires some kind of technological sophistication, which is still predominantly found in developed countries. Second, the majority of the research and development efforts in the health sector are still undertaken in developed countries. Another reason is that markets for pharmaceutical products and medical devices are dominated by companies based in developed countries. However, the recent trend towards a stronger participation of developing countries in global exports of health goods seems to indicate that developing countries have become more and more successful in their R&D efforts and in the production of competitive health products.
Graph 4: Exports of health products by country group (1995-2009)
Source: COMTRADE, WTO Secretariat
It is worthwhile looking more in detail at specific countries that are active in the import and export of health products. Table 1 lists the top 20 exports and imports of health products as defined in our sample for the year 2009. Looking at the top importers, we observe that the EU and the US account for almost half of worldwide imports. Japan, Switzerland and Canada together hold a share of 15 per cent. Interestingly, Switzerland imports more health products than China and Brazil taken together.
Overall, the first top ten top importers account for over 77 per cent of global imports. Four out of the top ten importers are developing countries. All other countries that are ranked 21 and lower have a share of less than 2 per cent in the global import market.
Turning to the main exporters, the picture is even more skewed towards a handful of major exporting countries. The EU, the US and Switzerland cover 73 per cent of global exports of health products.
Three developing countries, namely China, India and Mexico, are among the top ten exporters, however they only account together for around 9 per cent of global exports. Summing up the export shares of the top ten exporters totals 92 per cent of the global export market.
Some words of caution about the above analysis might be in order at this stage. First of all, we have considered the European Union as a single importer and exporter and thereby excluded all trade flows within the European Union. If we had taken intra-EU trade flows into account, the overall picture would have been more skewed towards developed countries. Second, trade data always suffer to some extent from the problem of transhipments. Health products might be imported in order to be reexported. Economies which are important redistribution hubs, such as Singapore or Hong Kong, might therefore register excessively high levels of imports and exports. It is not always possible to correct for these transhipments as not all countries report their re-exports or re-imports. For those countries in our sample that have reported re-export or re-imports we did not find a significant difference to regular import and export data. although an improvement has occurred, it has been rather modest compared to the other country groups. Looking only at data on imports per capita it is difficult to give an accurate explanation why
LDCs are relatively falling behind. The trade patterns are probably a reflection of various elements, such as slow economic growth or limited resources available for health at the public and private level. can be subject to changes, but the bound rates serve as upper ceilings. In the following, we will first analyse the evolution of applied tariff rates and we then study the difference between applied and bound tariff rates.
The data presented below only includes tariff data from WTO Members and other countries for which information is available in the WTO Integrated Database. For some countries tariff data is not available for any of the four points in time, and therefore these countries are excluded from our sample (see Appendix 3 for list of countries included). The tariff data for each commodity group is trade weighted, meaning that tariffs levied on larger imports are given more weight compared to smaller imports. 
Graph 8: Latest applied tariffs (trade weighted) by LDCs in six groups
Source: COMTRADE, WTO Secretariat per cent in 2009 and the applied tariffs on specific inputs into the pharmaceutical industry (A3) was lowered from 4 to 3.3 per cent. Applied tariffs on chemical inputs of general purpose (B) was decreased slightly from 4.7 per cent to 4.4 per cent. Imposing lower tariff on inputs into the pharmaceutical industry compared to final products is an indication of a policy attempting to promote the local production of pharmaceuticals. The applied tariffs on subgroups C1 and C2 remained almost identical at around 7.2 and 5.1 per cent, respectively. Looking together at all product groups, one observes only a modest decline in applied tariffs on health products over the past decade. The overall level of tariff ranges today between 3.3 (A3) and 8.2 per cent (A1).
Graph 9: Applied tariffs (trade weighted) by transition economies in six groups
Source: COMTRADE, WTO Secretariat In summary, the tariff rates applied on health products by the four country groups have decreased over the past fifteen years. In developed countries and in LDCs applied tariffs on medicines (A1 and A2) seem to be either zero or negligibly low, whereas in developing countries and transition economies they apparently still play an important role. All four country groups keep applied tariffs between 3.2 and 7.3 per cent on chemical inputs of general purpose (B). As for C1 (hospital and laboratory inputs) and C2 (medical technology equipment), all country groups apply higher tariffs for C1 than C2, except for LDCs. It is not straightforward to explain this observation, as C2 contains more final products than C1 and in case of tariff escalation should have the higher tariff level. Overall, we observe that applied tariffs on health products are low, however, in all country groups there is room for further lowering tariffs and thus for improving access.
Instead of studying country groups, one might be interested in knowing the level of applied tariff levied by individual countries. Table 2 Maldives and Rwanda are listed four times. It seems difficult to understand why these rather small countries maintain relatively high tariffs on health products and thereby pushing up domestic prices for these products. This is even more surprising when considering that these countries have no or only a small domestic production of these goods. loss of trade). Reducing the bound rates closer to the applied rate would provide an important signal to traders that tariffs will remain at low levels and therefore provide more predictability to both exporters and importers. For LDCs the bound rate is even higher reaching the level of around 40 per cent for all product groups, except for A3 which is bound above 60 per cent. Currently, only one transition countries, namely Albania, is WTO Members and has reported its tariffs. The applied and final bound rates are similar and show small absolute gaps. 
Preferential tariffs and tariff concessions
The above tariff analysis is based on tariff concessions that WTO Members grant at the multilateral level. WTO Members are allowed under certain conditions to conclude preferential trade agreements among themselves and also with non-Members. As the name already indicates, preferential trade agreements offer a level of market entry which is more favourable than the one committed at the multilateral level. As a consequence, the customs duties applied to imports from PTA partners are usually lower than the ones applied towards non-PTA partners. This section attempts to presents evidence of preferential tariffs applied by developing countries on health and health-related products for imports from other developing countries. We only include developing countries in our sample, as a large proportion of developed countries already grant duty-free or close to duty-free market access to imports on health and health-related products as we have seen above.
Preferential tariff data is rather difficult to obtain and it is not systematically notified to any international organization. The International Trade Centre (ITC) in Geneva has recently undertaken major efforts to collect the preferential tariff rates of major developing country exporters. In this section, we present the preferential tariff data collected by ITC as they apply to health products.
Looking at the aggregate level (Table 3) India is the country with the highest tariffs (both MFN and preferential) on health products in our sample. However, India is also the country which has lowered most drastically (in relative and absolute terms) its tariffs over the past five years. The difference between MFN and preferential rates is small in the case of India.
Like Chinese Taipei, South Africa maintains very low tariff levels on import of health product. In summary, analysing preferential tariffs we observe that tariffs are indeed lower compared to MFN, however, the difference does not exceed 1 per cent. Studying individual countries, the tariff level for health products, both preferential and MFN, differs substantially between countries. While for example Chinese Taipei and South Africa maintain low tariff rates, India imposes substantially higher tariff rates on trade towards the rest of the world as well as preferential trading partners. However, the difference between preferential rates and MFN is often small (below) 1 per cent and is biggest for case of China in 2009 (2.2 per cent lower tariffs).
IV. CONCLUSION
The first objective of this paper has been to establish a group of commodities based on the HS classification that are all important goods (as inputs or final products) entering the public health sphere. We suggest three commodity groups and five commodity subgroups to capture all international trade flows relevant for public health.
The paper then gave an overview of the corresponding international trade flows from 1995 to 2009.
We found that the international trade in health products have grown in a very dynamic way, especially trade in dosified and bulk medicines. Our results further indicate that international trade in health products is strongly dominated by trade among a small number of developed countries. Studying detailed tariff data at the multilateral level, we show that the tariff level has decreased significantly over the past fifteen years and is on average well below ten per cent. Tariffs in preferential trade arrangements are even lower.
Overall, tariffs on health products have come down substantially over the past years, and in many countries tariffs on health products are probably among the smaller obstacles for access to health. As a corollary, in the majority of countries applied tariffs are not used anymore as an instrument of industrial policy. One reason might be that the production of pharmaceutical and of medical devices typically requires a certain degree of technical sophistication which cannot be easily created or promoted. However, given these difficulties and the already low level of tariffs, the question to ask is why countries even maintain tariffs on health products. Imposing tariffs typically translates into higher product prices, especially in presence of long supply changes. Maintaining tariffs ultimaty means taxing the sick and creating additional costs for the health system.
Reducing the gap between international prices and domestic prices by lowering tariffs would therefore not only be a positive development for patients, but also for all health service providers that rely on cheap inputs of health products. In addition, lower prices for specific and general chemical inputs into the pharmaceutical industry (groupings A3 and B1) can also help promoting the competitiveness of the local pharmaceutical industry.
As several studies indicate, there are various factors that determine the domestic price of internationally traded health products (e.g. Cameron et al. 2011 ). These factors might include pricing strategies of the manufacturers, tariffs and non-tariff barriers, transportation and distribution costs, domestic taxes and other mark-up costs. Import tariffs levied on the value of an imported good thus constitute only one cost element. However, they can substantively alter the price of both, the final products as well as of intermediated inputs. In this paper, we only focus on tariffs and neglect other price determinants. In a study by Bate & Tren (2005) , the authors combine tariff data with data on value added tax and other duties and find that all duties taken together constituted a major impediment for access to medicine.
Another topic for future research could be to analyse special import regimes for health products.
Many countries exempt certain products from customs duties for various reasons, for example the government or international agencies often do not pay import duties on products imported for official purposes. Krasovec & Connor (1998) mention several countries that provide such tariff exemptions for public health commodities, especially the products are purchased by a non-profit buyer. In order to be able to evaluate the effect of such duty exemptions in a systematic way, one would need very detailed import data which specify for every import flow whether a duty was paid or not. The World Bank has recently launched the Tariff Reform Impact Simulation Tool (TRIST) which attempts to estimate the impact of trade reforms on trade flows by using highly disaggregated trade flows. Due to this new tool, 8 detailed national data is available with the necessary level of disaggregation. 9 As an extension of this paper, it would certainly be worthwhile retrieving this type of information and providing an in-depth analysis.
As indicated above, tariff data give only limited insights into the final price of health products in the importing countries, as other cost elements might play an important role. 10 Looking only at tariffs in isolation, one is unable to make predictions about final prices in countries, even less to make 8 http://web.worldbank.org/WBSITE/EXTERNAL/TOPICS/TRADE/0,,contentMDK:22326433~pagePK:210058 piPK:210062~theSitePK:239071,00.html 9 TRIST has been used for Albania, Bolivia, Ethiopia, Jordan, Kenya, Madagascar, Malawi, Mauritius, Morocco, Mozambique, Nigeria, Seychelles, Syria, Tanzania, Tunisia, and Zambia.
10 Woodward (2001) observes that countries with low tariffs often had higher medicines' prices than countries with high tariffs. comparisons across countries. From a trade perspective, lowering tariffs should result in lower prices and thus an increased demand for health products. Instead of thus looking at the absolute price level, one interesting research question would be to verify whether the decrease in tariffs has resulted in larger amounts of importations.
11 If lowering prices has indeed led to more imports, the question asked in the title of this paper would probably have a positive answer.
V.
11 In order to test this hypothesis one might construct a simple econometric model, which stipulates that the change in imports is explained by a change in tariffs. Higher imports might not only stem from lower tariffs, but demand might have increased for other reasons, such as higher private and public spending for health care or a changing age structure. In order to controll for these changes, one would need to introduce into the econometric three additional variables, namely the change in per capita income (GDP/Pop), the change in public health spending per capita (HeX/Pop) and finally the change in life expectancy (Lexp). The equation to be estimated could take the following form (all variables are included for all countries, i, in the sample. ε constitutes the error term): ∆im = α + ∆(tariff ) + ∆ + ∆ + ∆Lexp + ε 
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